Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China; Fytagoras B.V., Leiden 2333BE, The Netherlands; Leiden University-European Center for Chinese Medicine and Natural Compounds, Institute of Biology Leiden, Leiden University, Leiden 2333BE, The Netherlands.
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
Pharmacol Res. 2021 Apr;166:105472. doi: 10.1016/j.phrs.2021.105472. Epub 2021 Feb 14.
The coronavirus disease 2019 (COVID-19) has now rapidly spread around the world, causing an outbreak of acute infectious pneumonia. To develop effective and safe therapies for the prevention and treatment of COVID-19 has become the major global public health concern. Traditional medicine (TM)/herbal medicines (HMs) have been used to treat multiple epidemics in human history, which brings hope for the fight against COVID-19 in some areas. For example, in China, India, and South Korea with traditional medication history and theory, the governments issued a series of guidelines to support TM/HMs in the medication of COVID-19. In contrast, other countries e.g. North American and European governments are typically silent on these practices, unless to warn of possible harm and overselling. Such difference is due to the discrepancy in culture, history and philosophical views of health care and medication, as well as unharmonized policies and standards in the regulation and legalization of TM/HMs among different areas. Herein, we reviewed the responses and scientific researches from seven selected countries on the policies and legalization of TM/HMs to treat COVID-19, and also analyzed the major challenges and concerns to utilize the traditional knowledge and resource.
新型冠状病毒病(COVID-19)已在全球迅速蔓延,引发急性传染性肺炎爆发。开发针对 COVID-19 的有效且安全的治疗方法已成为全球主要的公共卫生关注点。传统医学(TM)/草药(HM)已被用于治疗人类历史上的多次传染病,在某些领域为抗击 COVID-19 带来了希望。例如,在中国、印度和韩国等具有传统用药历史和理论的国家,政府发布了一系列指南,支持 TM/HM 用于 COVID-19 的治疗。相比之下,其他国家(如北美和欧洲国家)在这些做法上通常保持沉默,除非警告可能的危害和过度销售。这种差异源于文化、历史和医疗保健哲学观点的差异,以及不同地区 TM/HM 的监管和合法化政策和标准的不统一。在此,我们回顾了七个选定国家对 TM/HM 治疗 COVID-19 的政策和合法化的反应和科学研究,并分析了利用传统知识和资源所面临的主要挑战和关注点。